# Hebei Senlang Biotechnology Inc., Ltd. trials: 40 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 40 trials with Hebei Senlang Biotechnology Inc., Ltd. as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Hebei Senlang Biotechnology Inc., Ltd.: 40 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hebei-senlang-biotechnology-inc-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 27, 2026 | NCT07435779 | Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study | Hebei Senlang Biotechnology Inc., Ltd. | Early phase 1 | Recruiting | UC | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435779) |
| February 19, 2026 | NCT07421856 | Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1/2 | Not yet recruiting | Multiple Myeloma in Relapse, Multiple Myeloma Refractory | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421856) |
| November 24, 2025 | NCT07244406 | Assessment of Senl\_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL | Hebei Senlang Biotechnology Inc., Ltd. | Phase 2 | Recruiting | B-ALL | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244406) |
| November 24, 2025 | NCT07244380 | Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | Hebei Senlang Biotechnology Inc., Ltd. | Phase 2 | Not yet recruiting | T Lymphoblastic Leukemia/Lymphoma | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244380) |
| September 8, 2025 | NCT07161193 | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1/2 | Not yet recruiting | Autoimmune Diseases | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07161193) |
| November 18, 2023 | NCT06136364 | CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 | Recruiting | T-lymphoblastic Lymphoma, T-ALL | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06136364) |
| October 5, 2023 | NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | Hebei Senlang Biotechnology Inc., Ltd. | Early phase 1 | Unknown | Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06067581) |
| November 23, 2022 | NCT05626400 | Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Recruiting | T-cell Acute Lymphoblastic Leukemia/Lymphoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05626400) |
| November 17, 2022 | NCT05619861 | CAR-T Cells in the Treatment of Malignant Hematological Tumors | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | Lymphoma, B-Cell, Leukemia, B-cell, Leukemia, T-Cell, Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05619861) |
| November 16, 2022 | NCT05618041 | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Recruiting | Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05618041) |
| June 1, 2022 | NCT05398614 | SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 | Unknown | T-ALL, Lymphoma, T-Cell | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05398614) |
| May 24, 2022 | NCT05388695 | To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 | Recruiting | 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05388695) |
| May 24, 2022 | NCT05388305 | Universal CAR-γδT Cell Injection in the AML Patients | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | AML | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05388305) |
| April 19, 2022 | NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | Hebei Senlang Biotechnology Inc., Ltd. | Early phase 1 | Unknown | Glioblastoma Multiforme, Adult | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05333588) |
| February 7, 2022 | NCT05225831 | Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Early phase 1 | Unknown | CD19+ and CD 22+ B-ALL | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05225831) |
| January 25, 2022 | NCT05206071 | Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | Non-hodgkin's Lymphoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05206071) |
| June 24, 2021 | NCT04938115 | Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Completed | Leukemia, T Cell | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04938115) |
| June 16, 2021 | NCT04928105 | Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | Lymphoma, T-Cell | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04928105) |
| June 8, 2021 | NCT04916860 | Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell... | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04916860) |
| March 12, 2021 | NCT04796441 | Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | AML | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04796441) |
| March 11, 2021 | NCT04792593 | Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | B-ALL | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04792593) |
| December 14, 2020 | NCT04666168 | A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | Non-hodgkin's Lymphoma | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04666168) |
| December 11, 2020 | NCT04665076 | Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | Plasma Cell Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04665076) |
| December 11, 2020 | NCT04665063 | A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Not applicable | Unknown | Hodgkin's Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04665063) |
| November 13, 2020 | NCT04626765 | CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Early phase 1 | Unknown | Childhood Acute Lymphoblastic Leukemia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04626765) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 8 |
| Phase 1 | 8 |
| Phase 1/2 | 4 |
| Phase 2 | 2 |
| Not applicable | 18 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 29 |
| Recruiting | 6 |
| Not yet recruiting | 3 |
| Completed | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lymphoma | 7 |
| Multiple Myeloma | 6 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 |
| Lymphoma, Non-Hodgkin | 3 |
| Leukemia | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Leukemia, B-Cell | 2 |
| Lymphoma, B-Cell | 2 |
| Leukemia, T-Cell | 2 |
| Lymphoma, T-Cell | 2 |
| Uterine Cervical Neoplasms | 1 |
| Sarcoma | 1 |
| Burkitt Lymphoma | 1 |
| Plasmacytoma | 1 |
| Autoimmune Diseases | 1 |
| Recurrence | 1 |
| Disease | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Glioblastoma | 1 |
| Glioma | 1 |
| Hodgkin Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Biotechnology companies in the United States](https://specstream.ai/data/businesses/biotechnology-companies/united-states)
- [Pediatric cardiology practices in the United States](https://specstream.ai/data/businesses/pediatric-cardiology-practices/united-states)
- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
- [Art restoration companies in the United States](https://specstream.ai/data/businesses/art-restoration-companies/united-states)
- [College counseling companies in the United States](https://specstream.ai/data/businesses/college-counseling-companies/united-states)
- [Foundation repair contractors in the United States](https://specstream.ai/data/businesses/foundation-repair-contractors/united-states)
